Physician profile
Jong H Lee
NPI 1962464826
$23,458.43
in general payments reported to CMS, 2019-2025
27 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $290 · 2021: $262 · 2022: $287 · 2023: $930 · 2024: $4,059 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Food and Beverage: $2,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,541.12 |
| Food and Beverage | $2,541.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $19,718.06 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Abbvie INC. | $692.28 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $380.64 | 2022-2025 | Miebo, Vyzulta, Prolensa |
| Allergan, INC. | $293.91 | 2019-2022 | |
| Glaukos Corporation | $259.49 | 2019-2025 | Idosetr |
| Ocular Therapeutix, INC. | $213.73 | 2023-2024 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $213.08 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $194.57 | 2019-2023 | Cequa |
| Novartis Pharmaceuticals Corporation | $192.83 | 2019-2023 | |
| Amgen INC. | $190.66 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $186.95 | 2019-2025 | Rocklatan, Argos, Luxor |
| Tarsus Pharmaceuticals, INC. | $171.54 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $168.82 | 2021-2024 | |
| Merz North America, INC. | $94.79 | 2019 | |
| Dompe US, INC. | $72.37 | 2024-2025 | Oxervate |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $60.10 | 2021-2024 | Tecnis Iol |
| Merz Pharmaceuticals, LLC | $48.78 | 2021-2024 | Xeomin |
| Horizon Therapeutics Plc | $48.08 | 2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $47.86 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $41.47 | 2019-2021 | |
| Thea Pharma INC. | $40.44 | 2023-2024 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $24.52 | 2021 | |
| Iridex Corporation | $23.44 | 2023 | |
| Carl Zeiss Meditec USA, INC. | $22.23 | 2023 | Cirrus Hd-Oct |
| Mallinckrodt Hospital Products INC. | $21.16 | 2020 | |
| Sight Sciences, INC. | $20.89 | 2022 | |
| Oyster Point Pharma, INC. | $15.74 | 2024 | Tyrvaya, Ryzumvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jong Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.